If you lack insurance coverage or have been denied coverage, ZYDELIG ® AccessConnect ® may be able to help. If you have no insurance coverage The Patient Assistance Program can determine if your financial situation qualifies you to receive your medication free of charge.
Full Answer
Is Zydelig a PI3K inhibitor?
Zydelig Prices, Coupons and Patient Assistance Programs. Zydelig (idelalisib) is a member of the PI3K inhibitors drug class and is commonly used for Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoma and others.
What is Zydelig used for?
ZYDELIG is a prescription medicine used to treat adults with: in combination with Rituxan ® (rituximab) when CLL comes back after prior cancer treatment and when Rituxan treatment alone may be used due to other health problems. when the disease worsens after treatment with at least 2 prior medicines.
How much does Zydelig cost?
The cost for Zydelig oral tablet 100 mg is around $12,986 for a supply of 60 tablets, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans. Zydelig is available as a brand name drug only, a generic version is not yet available.
Is Zydelig approved for CLL?
ZYDELIG was approved based on response rates. Data are not yet available to show if ZYDELIG improves symptoms or survival. ZYDELIG should not be used as the first medicine to treat people who have been diagnosed with CLL, FL, or SLL, and should not be used in combination with bendamustine and/or Rituxan to treat people with FL.
What does ZYDELIG treat?
ZYDELIG (idelalisib) is indicated for the treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities.
Who owns idelalisib?
19, 2014-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Zydelig® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL).
Who manufactures ZYDELIG?
Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia.
What is the cost of Zydelig?
The cost for Zydelig oral tablet 100 mg is around $13,098 for a supply of 60 tablets, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.
Is idelalisib a chemotherapy?
Idelalisib is the generic name for the trade chemotherapy drug Zydelig®. In some cases, health care professionals may use the trade name Zydelig® when referring to the generic drug idelalisib. Drug type: Idelalisib is a targeted therapy.
Is Zydelig a chemotherapy?
Zydelig® is the trade name for the generic chemotherapy drug idelalisib. In some cases, health care professionals may use the generic name idelalisib when referring to the trade drug Zydelig®. Drug type: Zydelig® is a targeted therapy.
What is follicular lymphoma?
Follicular lymphoma is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. Follicular lymphoma develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally helps us fight infections.
Is Venetoclax FDA approved?
for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)...Development timeline for Venclexta.DateArticleApr 11, 2016Approval FDA Approves Venclexta (venetoclax) for Chronic Lymphocytic Leukemia with 17p Deletion6 more rows•Jan 28, 2021
What drug company makes Calquence?
AstraZeneca's new tablet formulation of Calquence (acalabrutinib) has been approved in the US for all current indications, including adult patients with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and for patients with relapsed or refractory mantle cell lymphoma (MCL), which is approved under ...
Who owns Rituxan?
Roche | MabThera / Rituxan (rituximab)
Who developed Obinutuzumab?
Obinutuzumab was created by scientists at GlycArt Biotechnology, which had been founded in 2000 as a spin-out company of the Swiss Federal Institute of Technology in Zurich to develop afucosylated monoclonal antibodies; GA101 was one of its lead products when it was acquired by Roche in 2005.
Who makes Obinutuzumab?
Genentech: Gazyva® (obinutuzumab) - Information for Healthcare Providers.